Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb Company and Emory University have signed a master clinical trial agreement to conduct clinical trials for Bristol-Myers' investigational compounds in the metropolitan Atlanta area, US.
Subscribe to our email newsletter
The agreement will initially focus on multiple clinical trial programs in oncology.
Bristol-Myers global development and medical affairs senior vice president Brian Daniels said the partnership is aligned with the company’s strategy, which holds the opportunity to selectively integrate the expertise of other organisations with its own to best meet the treatment needs of patients.
"Our expectation is that the shared commitment of providing innovative solutions for patients, the world-class talent at both organizations and the clinical trial expertise at Emory, will result in important advancements in the understanding of Bristol-Myers Squibb compounds and their potential for treating patients with devastating diseases, such as cancer," Daniels added.
The investigators from Emory University and affiliated institutions will conduct Phase II, Phase III and paediatric trials to advance the ongoing development of Bristol-Myers’s investigational medicine portfolio, mainly in oncology, metabolics, hepatitis C and immunoscience.